API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
AB-218 (safusidenib) is a novel, selective, potent, oral mIDH1 inhibitor, which is investigated for the treatment of Grades 2 or 3 recurrent or progressive mutant isocitrate dehydrogenase 1 (mIDH1) glioma, one of the most common types of adult primary brain cancer.
Lead Product(s): Safusidenib
Therapeutic Area: Oncology Product Name: AB-218
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Daiichi Sankyo
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2023
Details:
Safusidenib (also known as AB-218), is a small molecule mIDH1 inhibitor. Mutations in IDH1 are frequently found in various tumor types such as glioma, cholangiocarcinoma, and chondrosarcoma. Safusidenib has also shown high blood brain barrier penetration from prior studies.
Lead Product(s): Safusidenib
Therapeutic Area: Oncology Product Name: AB-218
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2022